STELLA PHARMA Receives Marketing and Manufacturing Approval in Japan for “Steboronine® Intravenous Drip Bag 9000mg/300mL

STELLA PHARMA CORPORATION (Head office: Chuo-ku, Osaka City, President: Tomoyuki Asano) hereby announces that its drug for Boron Neutron Capture Therapy (BNCT) Steboronine® intravenous drip bag 9000mg/300mL (Generic name: Borofalan [10B]; hereinafter referred to as Steboronine®) was approved today by the Ministry of Health, Labour and Welfare of Japan for the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer.